Biomea Fusion (BMEA) AI Stock Analysis

• Market Cap: $77.07M
• Dividend Yield: N/A
• Average Volume (3M): 2.40M
• Price to Earnings (P/E): ―
• Beta (1Y): 1.66
• Revenue Growth: N/A
• EPS Growth: 40.22%
• Country: US
• Employees: 79
• Sector: Healthcare
• Sector Strength: 45
• Industry: Biotechnology
• EPS (TTM): -0.27
• Shares Outstanding: 70,703,636
• 10 Day Avg. Volume: 5,869,688
• 30 Day Avg. Volume: 2,395,415
• PEG Ratio: -0.09
• Price to Book (P/B): 2.72
• Price to Sales (P/S): 0.00
• P/FCF Ratio: -1.16
• Enterprise Value/Market Cap: 0.36
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: -56.12
• Enterprise Value/Ebitda: -0.30
• 1Y Price Target: $6.00
• Price Target Upside: 450.46% Upside
• Rating Consensus: Moderate Buy
• Number of Analyst Covering: 4
• EPS Forecast (FY): N/A
• Revenue Forecast (FY): N/A

• Rating: 50 Neutral
• Price Target: $1.00 ▼(-8.26% Downside)

The score is primarily held back by weak financial performance (no revenue, large losses, and significant cash burn with a shrinking equity base). Offsetting this are improving technical momentum and a supportive, positive pipeline update from the recent JPM conference event, while valuation remains difficult to assess due to ongoing losses and no dividend.

Positive Factors

Differentiated diabetes candidate (icovamenib)

Updated JPM data show icovamenib produced durable HbA1c reductions, improved C‑peptide and beta‑cell markers with a generally favorable safety profile. This suggests a potential disease‑modifying profile that could structurally differentiate Biomea in diabetes and enable long‑term partnership or commercial opportunities.

Covalent chemistry platform and focused pipeline

Biomea’s covalent small‑molecule chemistry platform and concentrated pipeline (e.g., menin inhibitor BMF‑219 plus preclinical assets) create a repeatable discovery engine. Platform leverage supports multiple programs, licensing potential and durable R&D productivity beyond any single program outcome.

Relatively low financial leverage

The company’s modest debt burden (debt/equity ~0.44) reduces near‑term solvency pressure common in development‑stage biotechs. Lower leverage preserves flexibility to raise capital or structure partnerships without heavy interest expense, a durable advantage while programs progress.

Negative Factors

High cash burn

Operating cash flow of roughly -$87M in the TTM and persistently negative free cash flow create structural funding needs. Ongoing high burn increases dependency on external financing, heightens dilution risk and may force reprioritization or slowing of clinical programs if capital markets tighten.

Pre-revenue with sustained losses

The company remains pre‑revenue with a TTM net loss near $96M. Sustained losses mean continued reliance on capital raises rather than operating cash generation; structurally this limits self‑funding of development and increases execution risk tied to financing cycles.

Shrinking equity and asset base

Equity and assets have declined materially (equity from ~$169M to ~$16M TTM), eroding the company’s financial buffer. A reduced capital base heightens dilution risk on future raises, constrains strategic optionality and makes sustained program investment more dependent on favorable financing or partnerships.

Biomea Fusion Business Overview & Revenue Model

Company Description

Biomea Fusion, Inc., a biopharmaceutical company, focuses on the discovery and development of covalent small molecule drugs to treat patients with genetically defined cancers and metabolic diseases. Its lead product candidate is BMF-219, an orally bioavailable, potent, and selective covalent inhibitor of menin, a transcriptional regulator in oncogenic signaling in multiple cancers. The company was incorporated in 2017 and is headquartered in Redwood City, California.

How the Company Makes Money

Biomea Fusion makes money through the development and eventual commercialization of its proprietary small molecule drug candidates. The company invests in research and development to advance its drugs through clinical trials. Revenue generation is primarily expected to occur upon successful commercialization of these drugs, either directly or through partnerships and licensing agreements with larger pharmaceutical companies. Additionally, Biomea may engage in strategic collaborations to co-develop treatments, which can provide milestone payments and royalties contingent upon the success of the drug candidates.

Biomea Fusion Financial Statement Overview

Summary

Financials remain weak: no revenue reported, losses have expanded materially (TTM net loss about $96M), and cash burn is heavy (TTM operating cash flow about -$87M). While leverage is relatively low, equity and assets have fallen sharply, increasing funding and dilution risk.

Income Statement

Financial performance remains highly loss-making with no revenue reported across the annual periods provided and TTM (Trailing-Twelve-Months) also showing $0 revenue. Losses have expanded versus earlier years (net loss of about $96M in TTM vs ~$5M in 2020), indicating a business still in heavy investment mode with limited operating leverage today. A modest positive is that the net loss in TTM is smaller than the 2024 annual net loss, but profitability is still far from breakeven.

Balance Sheet

Leverage is relatively low (debt-to-equity ~0.44 in TTM (Trailing-Twelve-Months)), which is supportive for a development-stage biotech. However, the balance sheet has weakened meaningfully, with equity dropping from ~$169M (2023) to ~$52M (2024) and down to ~$16M in TTM, while assets have also declined (from ~$200M in 2023 to ~$55M in TTM). Returns on equity are deeply negative, reflecting ongoing losses and shrinking capital base, which increases financing and dilution risk if cash burn persists.

Cash Flow

Cash burn remains heavy: operating cash flow is about -$87M in TTM (Trailing-Twelve-Months) and free cash flow is similarly negative. Cash outflow improved versus 2024 (operating cash flow about -$120M), but free cash flow is still negative and the trend shows continued deterioration versus earlier years (e.g., much smaller burn in 2020). Free cash flow closely tracks net losses, signaling limited non-cash add-backs and reinforcing the need for ongoing external funding.

Breakdown	TTM	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	0.00	0.00	0.00	0.00	0.00	0.00
Gross Profit	-500.00K	0.00	0.00	0.00	0.00	-132.00K
EBITDA	-95.07M	-142.32M	-124.62M	-82.94M	-41.42M	-5.19M
Net Income	-95.71M	-138.43M	-117.25M	-81.83M	-41.57M	-5.32M
Balance Sheet
Total Assets	55.19M	79.94M	199.93M	129.31M	185.71M	62.53M
Cash, Cash Equivalents and Short-Term Investments	46.64M	58.28M	176.87M	113.05M	173.52M	61.70M
Total Debt	6.88M	8.77M	10.30M	2.29M	2.85M	259.00K
Total Liabilities	39.57M	28.36M	30.69M	20.77M	6.92M	57.36M
Stockholders Equity	15.62M	51.57M	169.24M	108.54M	178.78M	5.17M
Cash Flow
Free Cash Flow	-87.14M	-120.26M	-99.96M	-63.45M	-38.61M	-4.51M
Operating Cash Flow	-87.06M	-119.89M	-96.59M	-62.42M	-35.44M	-4.46M
Investing Cash Flow	-82.00K	-362.00K	-2.22M	27.34M	-33.35M	-51.00K
Financing Cash Flow	45.83M	1.67M	163.80M	1.24M	153.19M	65.97M

Biomea Fusion Technical Analysis

• Technical Analysis Sentiment: Negative
• Last Price: 1.09
• 50DMA: Negative
• 100DMA: Negative
• 200DMA: Negative
• MACD: Positive
• RSI: Neutral
• STOCH: Positive

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For BMEA, the sentiment is Negative. The current price of 1.09 is below the 20-day moving average (MA) of 1.32, below the 50-day MA of 1.28, and below the 200-day MA of 1.66, indicating a bearish trend. The MACD of -0.06 indicates Positive momentum. The RSI at 35.60 is Neutral, neither overbought nor oversold. The STOCH value of 14.87 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for BMEA.

Biomea Fusion Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
SEER	54 Neutral	$100.98M	-1.33	-25.74%	―	13.77%	-4.76%
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%
BMEA	50 Neutral	$77.07M	-0.46	-209.00%	―	―	40.22%
INO	47 Neutral	$114.73M	-0.65	-328.45%	―	-10.36%	42.36%
OVID	47 Neutral	$192.67M	-2.90	-60.06%	―	946.61%	-11.30%
AGEN	45 Neutral	$98.28M	―	―	―	-33.41%	81.19%
ATOS	43 Neutral	$45.55M	-1.50	-48.89%	―	―	-9.42%

Biomea Fusion Corporate Events

Biomea Fusion Highlights Diabetes Pipeline at JPM Conference

On January 14, 2026, Biomea Fusion presented updated data on its diabetes and obesity pipeline at the 44th Annual J.P. Morgan Healthcare Conference in San Francisco and concurrently refreshed its corporate presentation for ongoing use with investors and analysts. The company highlighted clinical and preclinical results for its lead candidate icovamenib, showing that a 12-week dosing regimen in severe insulin-deficient type 2 diabetes patients produced durable reductions in HbA1c and increased insulin secretion measured by C-peptide index up to nine months after treatment ended, alongside evidence of enhanced beta-cell mass and function and improved GLP-1 receptor and insulin transcript levels in human islets, with a generally favorable safety profile and low rates of serious adverse events, underscoring its bid to differentiate in a crowded diabetes market by targeting disease progression rather than symptoms.

The most recent analyst rating on (BMEA) stock is a Hold with a $1.50 price target. To see the full list of analyst forecasts on Biomea Fusion stock, see the BMEA Stock Forecast page.